Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD
Recruitment status was Not yet recruiting
THis study aims to determine whether frequent dosing of intravitreal injections of Ranibizumab (Lucentis) or Bevacizumab (Avastin), which act as VEGF inhibitors, has a deleterious effect on the retina, studied by electrophysiologic testing.
This prospective, non-randomized clinical study will include patients assigned to intravitreal injection of Ranibizumab or Bevacizumab due to neovascular AMD. The patients will undergo repeat ophthalmic evaluation and intravitreal injections every 4-6 weeks, as long as will be deemed necessary. Periodic electrophysiologic evaluation including Electroretinogram (ERG), electro-oculogram (EOG) and Visual Evoked Potentials (VEP) tests will be performed every 3 months.
Procedure: Electroretinography (ERG), Visual Evoked Potentials (VEP)
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Please refer to this study by its ClinicalTrials.gov identifier: NCT00533689
|Contact: Michaella Goldstein, MDfirstname.lastname@example.org|
|Contact: Shiri Soudry, MDemail@example.com|
|Departent of Ophthalmlogy, Tel Aviv Sourasky Medical Center||Not yet recruiting|
|Tel Aviv, Israel, 64239|
|Principal Investigator:||Michaella Goldstein, MD||Tel-Aviv Sourasky Medical Center|
|Study Director:||Anat Loewenstein, MD||Tel-Aviv Sourasky Medical Center|
|Study Chair:||Ido Perlman, PhD||Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel|